Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel

Trial Profile

Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel

Suspended
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 According to results presented at the 18th World Conference on Lung Cancer, between 6/2016 and 2/2017, 20 patients were enrolled.
    • 18 Oct 2017 Results (n=20) assessing combination pembrolizumab and low dose weekly carboplatin\paclitaxel for patients with recurrent\metastatic nsclc and performance status of 2, were presented at the 18th World Conference on Lung Cancer.
    • 05 Jul 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top